EXPEDITING DRUG DISCOVERY
Efficiently shorten the timeline from preclinical validation to Phase I clinical trials, while simultaneously anticipating the outcomes of Phase II clinical trials.
ENHANCING CLINICAL STUDIES
Experience a substantial reduction in the number of in vivo experiments, resulting in significant cost savings.
REFINING THE DESIGN OF EXISTING EXPERIMENTS
Optimize the chances of success in both in vivo and in vitro experiments, leading to reduced costs and shorter timelines for clinical validation.
CRAFTING NEW EXPERIMENTAL STUDIES
Pioneer the development of novel experimental settings, offering improved predictions of the toxicity profiles of medical products.”